



Biotech Daily

Wednesday July 6, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: MICRO-X UP 11%; PRESCIENT DOWN 8%**
- * **MICROBIO HOPES TO RAISE \$3m FOR INFECTID TEST**
- * **RESAPP SLEEPCHECKERX WINS FDA 501(k) CLEARANCE**
- * **ADMINISTRATORS INVITE EXPRESSIONS OF INTEREST FOR OVENTUS**
- * **DVT BACKS BULL IQ DOCA; POSSIBLE DIRECTOR OFFENCES**
- * **ALTERITY DOSES 1st PHASE II MSA PATIENT**
- * **PARADIGM: CANADA APPROVAL, UK SITE FOR PHASE III ZILOSUL TRIAL**
- * **JAPAN PATENT FOR IMMUTEP IMP761**
- * **LUMOS REQUESTS 'REGULATORY UPDATE' TRADING HALT**
- * **NEUROTECH TAKES 'NTI164 TRIAL RESULTS' HALT TO SUSPENSION**
- * **ALLIANZ TAKES 10% OF STARPHARMA**
- * **BRANDON'S CUREATOR EVENT TO ANNOUNCE GRANT WINNERS**

MARKET REPORT

The Australian stock market fell 0.52 percent on Wednesday July 6, 2022, with the ASX200 down 34.8 points to 6,594.5 points. Seventeen of the Biotech Daily Top 40 stocks were up, 18 fell, four traded unchanged and one was untraded. All three Big Caps fell.

Micro-X was the best, up 1.5 cents or 10.7 percent to 15.5 cents, with 125,451 shares traded; followed by Nanosonics up 10.3 percent to \$3.96, with 2.1 million shares traded. Mesoblast climbed 9.5 percent; Telix was up 8.1 percent; Dimerix and Uscom were up more than seven percent; Pharmaxis improved 6.1 percent; Avita was up 5.1 percent; Amplia and Cyclopharm were up more than three percent; CSL, Medical Developments, Nova Eye, Pro Medicus and Resmed rose more than two percent; with Atomo, Clinuvel, Cochlear, Cynata and Polynovo up by more than one percent.

Prescient led the falls, down 1.5 cents or 8.3 percent to 16.5 cents, with 637,020 shares traded. Actinogen lost 7.55 percent; Volpara fell 6.1 percent; Antisense and Orthocell were down more than five percent; Oncosil, Paradigm and Patrys fell four percent or more; Genetic Signatures, Next Science and Proteomics were down three percent or more; Emvision, Imugene and Starpharma shed more than two percent; Immunetep, Neuren and Opthea were down more than one percent; with Kazia down by 0.8 percent.

MICROBIO

Brisbane's Microbio says it is more than half-way to raising \$3 million to commercialize its Infectid-BSI bloodstream infection test.

Microbio the funds would be used to prepare for manufacturing and offset expected initial marketing and distribution expenses for Infectid-BSI.

The company said that Infectid-BSI had been developed "to detect 26 of the most common sepsis-causing bacteria and fungi in less than three hours".

Microbio said the technology targeted pathogens' DNA 'fingerprint', found at a specific point in each pathogen's genetic code with the aim of increasing sensitivity, and reducing the time and cost of the diagnostic process, allowing the identification of sepsis-causing pathogen species directly from blood without the need for pre-culture.

Microbio co-founder and chief scientific officer Dr Flavia Huygens said the company had Conformité Européenne (CE) mark for the Infectid-BSI test after clinical evaluation trials.

"We are looking forward to being in market with our tests later this year," Dr Huygens said.

Microbio chief executive officer Paul Carboon said the company's shareholder base "exceeds 50 entities or individuals, which triggered the move to become an unlisted public company".

"The latest capital raising is ongoing and has already generated more than half of the \$3 million target," Mr Carboon said.

Microbio said potential investors should contact the company at: info@microbio.com.au.

Microbio is a public unlisted company.

RESAPP HEALTH

Resapp says the US Food and Drug Administration has granted it 501(k) clearance to sell Sleepcheckrx in the US as a prescription-only, software-as-a-medical device.

Resapp said that upon receipt of a prescription, patients would be given a specific code allowing them to download Sleepcheckrx from the Apple company's applications store.

The company said that the Sleepcheckrx was an "at-home sleep test that screens adults for the risk of moderate to severe obstructive sleep apnoea by analyzing breathing and snore sounds recorded on an Apple Iphone".

Resapp said it planned to expand and seek 501(k) clearance for the software on Android devices "in the future".

Resapp managing-director Dr Tony Keating said the company was "delighted to have secured FDA clearance for Sleepcheckrx".

"With more than 20 million American adults suffering from sleep apnoea and the majority of those not knowing that they have the condition, this clearance unlocks a significant market opportunity for Resapp," Dr Keating said. "By using Sleepcheckrx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnoea, helping their patients take the first step to getting treatment."

Resapp fell half a cent or 3.7 percent to 13 cents with 6.3 million shares traded.

OVENTUS MEDICAL

Grant Thornton as administrators of Oventus says it is inviting non-binding expressions of interest for the recapitalization or purchase of the business or its assets.

Grant Thornton said that all non-binding offers would be due by 5pm (AEST) on July 27, 2022 and for more information contact: Michael McCann and Graham Killer of Grant Thornton as voluntary administrators at: Oventus@au.gt.com.

Oventus last traded at two cents.

IQ GROUP

DVT Group says it support a deed of company arrangement for IQ Group with Bull Capital Pty Ltd, and “have identified possible offences committed by directors”.

DVT as administrators of IQ Group said it recommended the deed of company arrangement from Bull Capital Pty Ltd a company incorporated on May 4, 2022, which DVT said would “provide more certainty to investors as a whole”.

The administrators said that Bull Capital was established by businessman Danny Stapleton and investor in IQ Group “but not involved in any way in the operations or management of the IQ Group”.

DVT said that Mr Stapleton was “disappointed at the outcome of his investment in the IQ Group but believes in the potential of the IQ Group’s technology and is seeking to ‘go again’ through a new entity”.

The administrators said their preliminary investigations had “identified possible offences committed by the directors” relating to care and diligence, good faith, use of position, use of information, and under their directors’ duties, but noted in each case that further investigation was required.

DVT said its preliminary investigations had identified poor controls over expenses, significant and sustained trading losses, inadequate cash flow, and excessive directors’ remuneration as factors that most likely contributed to IQ Group’s financial difficulties. The administrators said that its review of expense claims made by chief executive officer Dr George Syrmalis, Con Tsigounis, and Spiro Sakiris showed that “some of these expense claims appeared to be unreasonable with respect to their amount and circumstance,” but that further investigations were required.

DVT said that From December 201 to March 2022 Dr Syrmalis claimed \$546525 in expenses of which \$232,233 related to travel and leisure “including first-class and business class flights to the US, expensive hotels for accommodation, expensive dinners and lunches and expensive laptops”.

The administrators said that Dr Syrmalis claimed dock fees for a boat owned by a related party.

DVT said that Mr Tsigounis claimed \$286,192 expenses and “the majority related to donations made to Health and Development Aid Abroad (HADA) for the development of an orphanage.

IQ Group last traded at 12 cents.

ALTERITY THERAPEUTICS

Alterity says it has dosed the first patient of 60 patients in its 12-month, randomized, double-blind, placebo-controlled phase II trial of ATH434 in multiple system atrophy. Alterity said the study would explore the effect of ATH434 treatment on biomarkers such as aggregating alpha-synuclein and excess iron, both of which it said were important contributors to multiple system atrophy pathology.

Alterity chief executive officer, Dr David Stamler said that dosing the first patient was “a significant milestone for Alterity as we look to bring a potential new treatment option to individuals living with [multiple system atrophy]”.

“This is just the first step as we expect to expand enrolment in multiple regions over the second half of this year,” Dr Stamler said.

Alterity was up 0.05 cents or 3.3 percent to 1.55 cents with 4.1 million shares traded.

PARADIGM BIOPHARMACEUTICALS

Paradigm says Health Canada has authorized its phase III trial of pentosan polysulphate sodium (Zilosul) for knee osteo-arthritis.

Paradigm said it was awaiting ethics approval to open up-to 10 sites in in Canada.

In March, the company said it had UK approvals for the trial (BD: Mar 17, 2022).

Today, Paradigm said it had activated its first UK trial site at the University of Leeds, with screening and enrolment expected to “begin imminently”.

The company said it intended to open a total of seven sites across the UK, with the other sites to be opened “in the coming months”.

Paradigm fell 4.5 cents or 4.3 percent to \$1.005.

IMMUTEP

Immutep says the Japan Patent Office has granted it a patent relating to its pre-clinical immune-suppressant candidate IMP761.

Immutep said the patent, titled ‘Anti-LAG-3 Antibodies’, would provide IMP761 protection to September 1, 2036.

The company said the patent claims were “directed to ... IMP761, pharmaceutical compositions comprising IMP761 and the use of the compositions in the treatment of T-cell mediated inflammatory and autoimmune diseases”.

Immutep said that IMP761 had “the potential to address the root cause of auto-immune diseases by specifically silencing auto-immune memory T-cells that accumulate at the disease site and which express LAG-3 as an ‘exhaustion marker’ after being repeatedly stimulated with dominant self-peptides”.

Immutep fell half a cent or 1.6 percent to 31 cents with 1.3 million shares traded.

LUMOS DIAGNOSTICS

Lumos has requested a trading halt “pending an announcement ... in relation to a regulatory update”.

Trading will resume on July 8, 2022, or on an earlier announcement.

Lumos last traded at 16.5 cents.

NEUROTECH INTERNATIONAL

Neurotech has requested a suspension to follow a trading halt pending results from a phase I/II trial of its marijuana in paediatric autism spectrum disorder (BD: Jul 4, 2022).

Trading will resume on July 7, 2022 or the release of the announcement.

Neurotech last traded at 7.5 cents.

STARPHARMA

Allianz SE and related parties say they have increased their substantial holding in Starpharma from 36,910,063 shares (9.09%) to 41,249,500 shares (10.10%).

The Hong Kong and Jakarta-based Allianz Global Investors and PT Asuransi Allianz Life Indonesia said than in more than 300 transactions between June 7, 2021 and June 30, 2022, it bought and sold shares in Starpharma at prices ranging from 63 cents to \$1.48, with the largest single acquisition 1,300,000 shares at \$1.10 a share.

Starpharma fell 1.5 cents or 2.2 percent to 68 cents.

BRANDON CAPITAL

Brandon Capital says its biotechnology incubator Cureator will hold its first event to unveil the companies successful in receiving project funding in the first funding round.

Brandon said that Cureator was delivered by Brandon Biocatalyst, formerly the Medical Research Commercialisation Fund, and was supported by the Federal Medical Research Future Fund's \$80 million Early Stage Translation and Commercialisation Support Grant program, which supported medical innovation "by providing non-dilutive grant funding with an investor lens".

Brandon Capital said that the July 19, 2022 event would provide an update on Cureator's inaugural funding round and opportunities for researchers and small and medium sized enterprises.

The company said that funding recipients would discuss their projects and experience with the application process.

Brandon Capital said that Cureator was responsible for managing \$40 million of the Early Stage Translation and Commercialisation Support Grant program, which was "dedicated to supporting commercialization of both pre-clinical medical innovations and early clinical development of therapeutics".

The event will be held on Tuesday July 19, 2022 from 5.30pm to 7.30pm (AEST).

Brandon Capital said that any researcher or enterprise interested in finding out more about the Cureator program should register to attend virtually via Zoom at:

https://us06web.zoom.us/webinar/register/WN_vcXJm2laSXeLCP6myneUyw.